← Browse by Condition

Medical Condition

lung disease

Total Trials

33

Recruiting Now

33

Trial Phases

Phase 2, Phase 3, Phase 2, Phase 3

Pulmonary clinical trials span chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and rare ILDs β€” each with distinct pathophysiology and treatment targets. IPF research is particularly active, building on pirfenidone and nintedanib to identify anti-fibrotic combinations that slow disease more effectively.

Trials include inhaled triple combinations for COPD (LABA/LAMA/ICS), treprostinil subcutaneous for PAH, PDE4B inhibitors, anti-CCL2 antibodies for fibrosis, and aerosol gene therapy for CF (CFTR modulators plus mRNA). FEV1, 6-minute walk distance, and lung function decline remain core endpoints with patient-reported outcomes gaining weight.

Frequently Asked Questions — lung disease Clinical Trials

How many clinical trials are currently recruiting for lung disease?

ClinicalMetric currently tracks 33 actively recruiting clinical trials for lung disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 33. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for lung disease?

lung disease research spans Phase 1 (1 trial), Phase 2 (8 trials), Phase 3 (4 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a lung disease clinical trial?

Eligibility criteria for lung disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

1

Phase 2

8

Phase 3

4

Phase 4

1

Top Sponsors

Boehringer Ingelheim 2 trials

Shanghai Pulmonary Hospital, Shanghai, China 1 trial

University of Calgary 1 trial

Mayo Clinic 1 trial

Fundación GECP 1 trial

Recruiting Clinical Trials

NCT06758700 Phase 2

Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer

Shanghai Pulmonary Hospital, S...

Clinical Information System Impact on Hospitalized Patients With Chronic Disease

University of Calgary

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

NCT06431633 Phase 3

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Fundación GECP

O2 Versus CPAP Treatment Of Patients Undergoing SIPE Therapy (OCTOPUS)

Dalarna County Council, Sweden

The Effect of Spinal Mobilization on Respiratory Parameters in Parkinson's Disease Patients

Turkey (Türkiye)

Abant Izzet Baysal University

Ultrasound and Respiratory Physiological Signals in Lung Diseases

Fondazione Policlinico Univers...

NCT07441278 Phase 2

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

United States, Japan

NS Pharma, Inc.

Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

University Hospital Southampto...

NCT05878717 Phase 2, Phase 3

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

United States, Argen...

GlaxoSmithKline

NCT05922761 Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Dana-Farber Cancer Institute

Dorothy P. and Richard P. Simmons Center for ILD Research Registry

University of Pittsburgh

NCT07201922 Phase 3

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

United States, Argen...

Boehringer Ingelheim

NCT07366034 Phase 3

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

United States, Argen...

Boehringer Ingelheim

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Breathlessness Perceptions Within Respiratory Diseases

University Hospitals, Leiceste...

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

National Heart, Lung, and Bloo...

NCT05192057 Phase 4

Hypertonic Saline Inhalation for Mycobacterium Avium Complex Pulmonary Disease

Radboud University Medical Cen...

NCT03630211 Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases

University Hospital Olomouc

Trikafta Exercise Study in Cystic Fibrosis

University of British Columbia

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

University of Rochester

NCT07323732 Phase 2

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

Memorial Sloan Kettering Cance...

Validation of Soluble Programmed Death-1 in Predicting Progression of Nodular-bronchiectatic Form of Nontuberculous Mycobacterial Lung Disease: a Multi-Country Research

National Taiwan University Hos...

NCT06585020 Phase 2

Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection

Centre Hospitalier Universitai...

Connective Tissue Diseases and Lung Manifestations

Medical University Innsbruck

Home-based Pulmonary Rehabilitation in Interstitial Lung Disease

Post Graduate Institute of Med...

NCT07490041 EARLY_Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

The Children's Hospital of Zhe...

Prospective Study on Antimicrobial RESIstance in Chronic Pulmonary DiseasE

United States, Alban...

Fondazione IRCCS Ca' Granda, O...

Routine vs On-demand ECMO for Lung Transplantation

Centre hospitalier de l'Univer...

Practice of Oxygenation and Respiratory Support During Fiberoptic Bronchoscopy

University Magna Graecia

NCT06325696 Phase 2

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

National Institute of Environm...

Efficacy of Video-Based Interactive Game Therapy in Interstitial Lung Patients

Turkey (Türkiye)

Istanbul University

Related Conditions

interstitial lung disease (10) lung diseases (7) interstitial lung diseases (3) pulmonary hypertension (3) interstitial lung disease ild (3) chronic lung diseases (2) idiopathic pulmonary fibrosis (2) lung diseases interstitial (2) nontuberculous mycobacterial lung disease (2) systemic sclerosis (2) extensive stage small cell lung cancer es sclc (1) thoracic neoplasms (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology